The treatment of autoimmune diseases has long been plagued by the dilemma of "difficulty in precise regulation", and the abnormal activation of CD4 T cells is the core pathological link. Today, we focus on Forigerimod (CAS: 497156-60-2), a CD4 T cell-regulating polypeptide whose breakthrough progress in the research of diseases such as systemic lupus erythematosus (SLE) has become a focal point in the scientific community.
As a unique polypeptide consisting of 21 amino acids, Forigerimod is derived from the 70 kDa U1 small nuclear ribonucleoprotein and carries a phosphorylation modification at the Ser140 site. This distinctive structure endows it with precise targeting ability: it can not only block the activation of autoreactive CD4 T cells from the upstream pathway and inhibit abnormal inflammatory signals, but also robustly regulate chaperone-mediated autophagy—a mechanism proven to be closely associated with the progression of autoimmune diseases.
Animal experimental data provide strong evidence: in MRL/lpr lupus model mice, intravenous injection of a specified dose of Forigerimod significantly ameliorated salivary gland cell infiltration, repaired the abnormal autophagic process, and gradually restored the pathological tissues to normal. This suggests that it may open up a new avenue for autoimmune disease treatment by reconstructing immune homeostasis and repairing autophagic defects.
What is even more promising is its clinical translation value. Currently, Forigerimod has entered Phase Ⅲ clinical trials for the treatment of SLE in combination with standard regimens. The trial adopts a protocol of subcutaneous injection of 200 μg every 4 weeks for a continuous 48 weeks to evaluate its efficacy and safety . Compared with traditional non-specific immunosuppressants, it only targets abnormal T cells without impairing normal immune defense, which is expected to drastically reduce adverse reactions associated with treatment.
From basic mechanism research to clinical exploration, Forigerimod fully demonstrates the unique advantages of polypeptide modulators. For researchers, it serves as an excellent tool molecule for deciphering the pathology of autoimmune diseases; for SLE patients, the advancement of related trials undoubtedly brings new therapeutic hope and provides valuable insights for the precise treatment of similar diseases.
